The Filing Desk

Ascendis Pharma A/S vs TG Therapeutics

Ascendis Pharma A/S ASND · TG Therapeutics TGTX · Biotechnology

Ascendis Pharma A/S reported revenue of €720 million in fiscal 2025, and TG Therapeutics $616 million in fiscal 2025, in different currencies. Ascendis Pharma A/S's revenue grew 98.0% in its latest year, and TG Therapeutics' grew 87.3%. Ascendis Pharma A/S had an operating margin of -18.9%, against 20.0% at TG Therapeutics.

Side by side

Ascendis Pharma A/STG Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue€720M$616M
Revenue growth98.0%87.3%
Revenue growth a year, last 5 years152.6%398.6%
Gross margin86.8%83.7%
Operating margin−18.9%20.0%
Net margin−31.7%72.6%
Free cash flow—−$25M
Free cash flow margin—−4.0%
Return on capital—29.0%
Net debt to EBITDA—0.4x
Dividends and buybacks€17M$91M
Change in diluted share count4.7%0.7%
Last close$255.96$64.88
P/E at the last close—96.8×
Insider trades, last 12 monthsbought $777,068, sold $10.8 millionsold $437,650
Piotroski F-score5 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
In each company's own currency, fiscal years
Ascendis Pharma A/STG Therapeutics
Operating margin
Percent of revenue
Ascendis Pharma A/STG Therapeutics
Free cash flow
In each company's own currency. Cash from operations minus capital expenditure.
Ascendis Pharma A/STG Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ascendis Pharma A/S and TG Therapeutics pages.